Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report
nd successfully treated with this CDK4/6 inhibitor. A 73-year-old woman with bone metastatic breast cancer (hormone-positive, HER2-negative) was treated with abemaciclib, fulvestrant, denosumab, and precipitated calcium carbonate with cholecalciferol and...
Conclusions/Relevance: This case suggests that rechallenge with palbociclib after severe liver injury with abemaciclib may allow for continued treatment with CDK4/6 inhibitors.
Ultrasound-based radiomics model for predicting molecular biomarkers in breast cancer
Source : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1216446/full
BackgroundBreast cancer (BC) is the most common cancer in women and is highly heterogeneous. BC can be classified into four molecular subtypes based on the status of estrogen receptor (ER),...
Conclusion: Ultrasound-based radiomics provides a promising method for predicting molecular biomarker expression of ER, PR, HER2, and Ki-67 in BC.
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia - Cancer Cell International
Source : https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03000-x
Background Acute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating mutations in the FLT3 gene are common among patients and make...
Conclusions: This study suggests that a multi-targeted intervention involving a CDK4/6 inhibitor with a FLT3 inhibitor or a pan-PI3K inhibitor might be a valuable therapeutic strategy for AML to overcome drug resistance. Moreover, many patients cannot tolerate high doses of the drugs that were studied (quizartinib, palbociclib and PI3K...
Conclusion: CD10 can be used as an independent prognostic stromal marker and this will help to envisage new therapeutic strategies.
Safety and Feasibility of CDK4/6 Inhibitors Treatment Combined with Radiotherapy in Patients with HR-positive/HER2-negative Breast Cancer A Systematic Review and Meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37536378/
The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
Conclusion: The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.